Based on the Insulet Corporation stock forecast from 13 analysts, the average analyst target price for Insulet Corporation is USD 271.65 over the next 12 months. Insulet Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Insulet Corporation is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Insulet Corporation’s stock price was USD 266.57. Insulet Corporation’s stock price has changed by -1.03% over the past week, +1.38% over the past month and +23.31% over the last year.
No recent analyst target price found for Insulet Corporation
No recent average analyst rating found for Insulet Corporation
Company Overview Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Read Less
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in th...Read More
Frequently Asked Questions About Insulet Corporation (PODD) Stock
Based on ratings from 13 analysts Insulet Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 17 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on PODD's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for PODD is USD 271.65 over the next 12 months. The maximum analyst target price is USD 340 while the minimum anlayst target price is USD 220.
PODD stock's Price/Earning ratio is 45.88.
Our analysis grades PODD stock's Price / Earning ratio at F. This means that PODD stock's Price/Earning ratio is above 60% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PODD may be a overvalued for its sector.
The last closing price of PODD's stock was USD 266.57.
The most recent market capitalization for PODD is USD 19.01B.
Based on targets from 13 analysts, the average taret price for PODD is projected at USD 271.65 over the next 12 months.
This means that PODD's stock price may go up by +1.91% over the next 12 months.
We can't find any ETFs which contains Insulet Corporation's stock.
As per our most recent records Insulet Corporation has 3,000 Employees.
Insulet Corporation's registered address is 100 Nagog Park, Acton, MA, United States, 01720.
You can get more information about it from Insulet Corporation's website at https://www.insulet.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Insulet Corporation (PODD) Stock
Based on ratings from 13 analysts Insulet Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 17 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on PODD's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for PODD is USD 271.65 over the next 12 months. The maximum analyst target price is USD 340 while the minimum anlayst target price is USD 220.
PODD stock's Price/Earning ratio is 45.88.
Our analysis grades PODD stock's Price / Earning ratio at F. This means that PODD stock's Price/Earning ratio is above 60% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PODD may be a overvalued for its sector.
The last closing price of PODD's stock was USD 266.57.
The most recent market capitalization for PODD is USD 19.01B.
Based on targets from 13 analysts, the average taret price for PODD is projected at USD 271.65 over the next 12 months.
This means that PODD's stock price may go up by +1.91% over the next 12 months.
We can't find any ETFs which contains Insulet Corporation's stock.
As per our most recent records Insulet Corporation has 3,000 Employees.
Insulet Corporation's registered address is 100 Nagog Park, Acton, MA, United States, 01720.
You can get more information about it from Insulet Corporation's website at https://www.insulet.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PODD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
